Market Overview:
The global Parkinson's disease treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Parkinson's disease, rising awareness about available treatments, and technological advancements in Parkinson's disease treatment therapies. The global Parkinson's disease treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into oral therapies, transdermal therapies, subcutaneous therapies, and intestinal infusion therapies. Oral therapy is further sub-segmented into dopaminergic drugs and non-dopaminergic drugs. Transdermal therapy is further sub-segmented into apomorphine patches and rotigotine patches. Subcutaneous therapy is further sub-segmented into levodopa/carbidopa injections and bromocriptine mesylate injections Intestinal infusion therapy is further sub-segmented into entacapone tablets/capsules and tolcapone tablets/capsules. On the basis of application, the market is segmented into hospital pharmacy (inpatient), retail pharmacy (outpatient), online pharmacy (home care).
Product Definition:
Parkinson's disease is a chronic and progressive movement disorder that affects the central nervous system. It is caused by the death of dopamine-producing cells in the brain. There is no cure for Parkinson's disease, but there are treatments available that can help relieve symptoms. Treatment options include medications, surgery, and lifestyle changes. The goal of treatment is to reduce symptoms and improve quality of life.
Oral:
Oral, it's usage and growth factor in Parkinson's Disease Treatment market is a new treatment approach that involves the use of oral medications to control the symptoms of Parkinson’s disease. The current treatments for this condition usually involve deep brain stimulation or implantable neurostimulators which deliver electrical impulses to the brain to relieve symptoms. However, these procedures have several side effects such as nausea and vomiting, loss of balance ability, etc.
Transdermal:
Transdermal patches are adhesive devices that allow the transmission of drugs through the skin. They are most commonly used for treating conditions such as Parkinson’s disease and Alzheimer’s disease. Transdermal patches contain chemicals that are released into the body over a period of time, these chemicals then travel to targeted areas via nerve fibers and produce therapeutic effects in the brain.
Application Insights:
The market is segmented by application into hospital pharmacy, retail pharmacy, online pharmacy and others. Hospital pharmacies are expected to dominate the market owing to the presence of a large patient base with PD and increasing awareness among healthcare professionals about PD treatment options. The growing number of hospitals & pharmaceutical centers coupled with rising demand for effective Parkinson¢â‚¬â„¢s disease treatment is anticipated to drive growth over the forecast period.
Retail pharmacies are also expected to grow at lucrative rates during the forecast period due largely to an increase in health consciousness among consumers as well as healthcare providers which has resulted in increased focus on new treatments for PD through these channels. Additionally, high product penetration by manufacturers such as Teva Pharmaceuticals USA; Pfizer; Mylan N.V.; Sun Pharmaceutical Industries Ltd.; Novartis; and others is further estimated to contribute towards industry growth over the next few years.
Regional Analysis:
North America dominated the global Parkinson’s disease treatment market in 2017. The presence of well-established healthcare facilities, availability of highly advanced medical products and high awareness levels amongst people are some factors responsible for its large share. Moreover, increasing prevalence of neurodegenerative conditions such as Parkinson’s disease is also expected to drive the demand for these drugs in this region. According to an article published by NCBI, around 60 thousand patients suffer from PD in North America which is approximately 0.6% of world population suffering from neurodegenerative disorders at any point in time (2017).
Asia Pacific market was valued at USD X million in 2017 and it is anticipated to grow with a lucrative CAGR over the forecast period owing to rising disposable income coupled with growing health awareness amongst people especially towards mental health issues due to social media influence and other forms of mass communication (Ongoing Clinical Trials).
Growth Factors:
- Increasing incidence of Parkinson's disease
- Growing awareness about Parkinson's disease and its treatment options
- Rising demand for better and more effective treatments for Parkinson's disease
- Availability of government funding for research on Parkinson's disease
- Technological advancements in the field of Parkinson's disease treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Parkinson’s Disease Treatment Market Research Report
By Type
Oral, Transdermal, Subcutaneous, Intestinal Infusion
By Application
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
By Companies
Teva, Roche, Prothena, Acorda Therapeutics, Voyager Therapeutics, Impax Pharmaceuticals, UCB, AbbVie, MSD, Orion Pharmaceuticals, Intec Pharma, NeuroDerm, Adamas Therapeutics, Acadia, Sunovion, GSK
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Parkinson’s Disease Treatment Market Report Segments:
The global Parkinson’s Disease Treatment market is segmented on the basis of:
Types
Oral, Transdermal, Subcutaneous, Intestinal Infusion
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Roche
- Prothena
- Acorda Therapeutics
- Voyager Therapeutics
- Impax Pharmaceuticals
- UCB
- AbbVie
- MSD
- Orion Pharmaceuticals
- Intec Pharma
- NeuroDerm
- Adamas Therapeutics
- Acadia
- Sunovion
- GSK
Highlights of The Parkinson’s Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Transdermal
- Subcutaneous
- Intestinal Infusion
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Parkinson’s Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for Parkinsonu00e2u20acu2122s Disease, but there are treatments that can help improve the symptoms. Treatment options may include medication, surgery, and physical therapy.
Some of the major companies in the parkinson’s disease treatment market are Teva, Roche, Prothena, Acorda Therapeutics, Voyager Therapeutics, Impax Pharmaceuticals, UCB, AbbVie, MSD, Orion Pharmaceuticals, Intec Pharma, NeuroDerm, Adamas Therapeutics, Acadia, Sunovion, GSK.
The parkinson¢‚¬„¢s disease treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Parkinson’s Disease Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Parkinson’s Disease Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Parkinson’s Disease Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Parkinson’s Disease Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Parkinson’s Disease Treatment Market Size & Forecast, 2018-2028
4.5.1 Parkinson’s Disease Treatment Market Size and Y-o-Y Growth
4.5.2 Parkinson’s Disease Treatment Market Absolute $ Opportunity
Chapter 5 Global Parkinson’s Disease Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Parkinson’s Disease Treatment Market Size Forecast by Type
5.2.1 Oral
5.2.2 Transdermal
5.2.3 Subcutaneous
5.2.4 Intestinal Infusion
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Parkinson’s Disease Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Parkinson’s Disease Treatment Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Online Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Parkinson’s Disease Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Parkinson’s Disease Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Parkinson’s Disease Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Parkinson’s Disease Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Parkinson’s Disease Treatment Market Size Forecast by Type
9.6.1 Oral
9.6.2 Transdermal
9.6.3 Subcutaneous
9.6.4 Intestinal Infusion
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Parkinson’s Disease Treatment Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Online Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Parkinson’s Disease Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Parkinson’s Disease Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Parkinson’s Disease Treatment Market Size Forecast by Type
10.6.1 Oral
10.6.2 Transdermal
10.6.3 Subcutaneous
10.6.4 Intestinal Infusion
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Parkinson’s Disease Treatment Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Online Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Parkinson’s Disease Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Parkinson’s Disease Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Parkinson’s Disease Treatment Market Size Forecast by Type
11.6.1 Oral
11.6.2 Transdermal
11.6.3 Subcutaneous
11.6.4 Intestinal Infusion
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Parkinson’s Disease Treatment Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Online Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Parkinson’s Disease Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Parkinson’s Disease Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Parkinson’s Disease Treatment Market Size Forecast by Type
12.6.1 Oral
12.6.2 Transdermal
12.6.3 Subcutaneous
12.6.4 Intestinal Infusion
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Parkinson’s Disease Treatment Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Online Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Parkinson’s Disease Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Parkinson’s Disease Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Parkinson’s Disease Treatment Market Size Forecast by Type
13.6.1 Oral
13.6.2 Transdermal
13.6.3 Subcutaneous
13.6.4 Intestinal Infusion
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Parkinson’s Disease Treatment Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Online Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Parkinson’s Disease Treatment Market: Competitive Dashboard
14.2 Global Parkinson’s Disease Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Roche
14.3.3 Prothena
14.3.4 Acorda Therapeutics
14.3.5 Voyager Therapeutics
14.3.6 Impax Pharmaceuticals
14.3.7 UCB
14.3.8 AbbVie
14.3.9 MSD
14.3.10 Orion Pharmaceuticals
14.3.11 Intec Pharma
14.3.12 NeuroDerm
14.3.13 Adamas Therapeutics
14.3.14 Acadia
14.3.15 Sunovion
14.3.16 GSK
